Geovax to present at the h.c. wainwright 25th annual global investment conference

Company to provide updates on multiple phase 2 clinical trials  for geo-cm04s1 and gedeptin® atlanta, ga, aug. 31, 2023 (globe newswire) -- via newmediawire – geovax labs, inc. (nasdaq: govx), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that it will present a company overview and host investor meetings during the h.c. wainwright 25th annual global investment conference being held september 11-13, 2023 in new york city.
GOVX Ratings Summary
GOVX Quant Ranking